Citigroup’s Elicio Therapeutics ELTX Stock Holding History

Citigroup’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,658	Closed	-$117K	–	6160
2025 Q3	$117K	Buy	+10,658	New	+$108K	﹤0.01%	4205
2025 Q1	–	Sell	-374	Closed	-$1.83K	–	5685
2024 Q4	$1.83K	Hold	374	–	–	﹤0.01%	5553
2024 Q3	$1.88K	Hold	374	–	–	﹤0.01%	5419
2024 Q2	$1.54K	Hold	374	–	–	﹤0.01%	5350
2024 Q1	$2.84K	Hold	374	–	–	﹤0.01%	5366
2023 Q4	$3.12K	Hold	374	–	–	﹤0.01%	5378
2023 Q3	$3.16K	Hold	374	–	–	﹤0.01%	4844
2023 Q2	$3.55K	Hold	374	–	–	﹤0.01%	5223
2023 Q1	$2.17K	Hold	374	–	–	﹤0.01%	5084
2022 Q4	$3.04K	Hold	374	–	–	﹤0.01%	5142
2022 Q3	$3K	Sell	374 -17	-4%	-$178	﹤0.01%	5376
2022 Q2	$4K	Sell	391 -405	-51%	-$6.47K	﹤0.01%	5671
2022 Q1	$17K	Sell	796 -135	-15%	-$3.05K	﹤0.01%	5242
2021 Q4	$27K	Buy	931 +683	+275%	+$34.5K	﹤0.01%	5305
2021 Q3	$24K	Buy	248 +220	+786%	+$23.8K	﹤0.01%	5152
2021 Q2	$4K	Sell	28 -11	-28%	-$1.59K	﹤0.01%	5870
2021 Q1	$7K	Buy	+39	New	+$7.53K	﹤0.01%	5800

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's ELTX Position: Q4 2025 in Review

Citigroup sold out of Elicio Therapeutics (ELTX) in Q4 2025, closing a stake of 10,658 shares — an estimated $117K sold.

Citigroup first reported a position in ELTX in Q1 2021 and held it in 17 quarters. The position peaked at $117K in Q3 2025. 37 funds tracked by Wall St. Rank hold ELTX as of Q4 2025.

Citigroup reported no remaining Elicio Therapeutics position as of Q4 2025 after selling out during the quarter.
Citigroup sold 10,658 Elicio Therapeutics shares in Q4 2025, an estimated $117K.
Citigroup first reported a position in Elicio Therapeutics in Q1 2021 and held it in 17 quarters.
Citigroup's Elicio Therapeutics position peaked at $117K in Q3 2025.
37 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.